专题：Cancer Treatment and Pharmacology

This cluster of papers focuses on the chemotherapy-induced peripheral neuropathy (CIPN) experienced by cancer patients, particularly in the context of breast cancer treatment. It covers various aspects such as the neurotoxic effects of taxanes and oxaliplatin, neuroprotective strategies, and the impact of CIPN on the quality of life of patients. Additionally, it discusses the use of microtubule-targeting agents like Eribulin Mesylate in cancer treatment.
最新文献
Fluoropyrimidine-induced cardiotoxicity: outcomes and safety of chemotherapy reintroduction in a retrospective cohort study

article Full Text OpenAlex

Daratumumab or active observation for asymptomatic biochemical relapse in patients with multiple myeloma

article Full Text OpenAlex

Abstract RF6-05: Patient-reported outcomes (PROs) with sacituzumab govitecan (SG) vs chemotherapy in patients with previously untreated advanced triple-negative breast cancer (TNBC) who are not candidates for PD-(L)1 inhibitors in the phase 3 ASCENT-03 study

article Full Text OpenAlex

Abstract RF2-03: Adjuvant epirubicin plus cyclophosphamide followed by taxanes with or without carboplatin for early stage triple-negative breast cancer (RJBC 1501): a randomized controlled phase III trial

article Full Text OpenAlex

Abstract RF2-04: Effect of adjuvant carboplatin intensified chemotherapy versus standard chemotherapy on survival in women with high-risk early-stage triple-negative breast cancer (CITRINE): a phase 3 randomized trial

article Full Text OpenAlex

Abstract GS1-01: Her2climb-05: a randomized, double-blind, phase 3 study of tucatinib versus placebo in combination with trastuzumab and pertuzumab as maintenance therapy for her2+ metastatic breast cancer

article Full Text OpenAlex

Time‑resolved multi-omic analysis of paclitaxel exposure in human iPSC‑derived sensory neurons unveils mechanisms of chemotherapy‑induced peripheral neuropathy

article Full Text OpenAlex

Abemacilib‐Related Radiation Recall Dermatitis Post Breast Reconstruction: A Case Report and Literature Review

article Full Text OpenAlex

An oBservational retrospective Analysis of treatment patternS and Effectiveness of standard of CAre for Multiple Myeloma Patients Exposed to Lenalidomide and a Proteasome Inhibitor: BasecaMMp Study

article Full Text OpenAlex

Protective effect of new histone deacetylase 6 inhibitors in a cisplatin-induced peripheral neurotoxicity murine model

article Full Text OpenAlex

近5年高被引文献
Pharmacological Reviews

review Full Text OpenAlex 2675 FWCI0

Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer

article Full Text OpenAlex 1049 FWCI105.6859

BindingDB Entry 50022499: ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy.

article Full Text OpenAlex 933 FWCI0

Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial

article Full Text OpenAlex 589 FWCI58.9121

Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C

article Full Text OpenAlex 446 FWCI44.0576

Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma

article Full Text OpenAlex 440 FWCI66.0763

NCCN Guidelines® Insights: Breast Cancer, Version 4.2023

article Full Text OpenAlex 411 FWCI94.6936

Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer

article Full Text OpenAlex 386 FWCI94.4603

Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management

review Full Text OpenAlex 381 FWCI84.9338

Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial

article Full Text OpenAlex 377 FWCI55.3241